Published on October 26, 2009 at 4:37 AM
Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that positive data from two investigator-initiated studies with ZEGERID® (omeprazole/sodium bicarbonate) will be presented in poster sessions at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting taking place in San Diego. These studies were supported by grants from Santarus.
Poster P424: Randomized Open-Label Trial to Assess the Impact of Dosage Timing of Omeprazole/Sodium Bicarbonate (Zegerid 40 mg) on Healing of Severe Reflux Esophagitis: Preliminary Results
(D Francis, MD, et al) - Monday, October 26, 2009, 10:30 a.m. – 4:00 p.m. Pacific Time
This poster discusses preliminary results from a prospective open-label study with ZEGERID 40 mg administered for 8 weeks, either in the morning before breakfast or at bedtime, in treating subjects with severe erosive esophagitis (LA Grade C and D). For optimal efficacy, proton pump inhibitors (PPIs) are taken on an empty stomach 20 to 60 minutes before a meal, which can be cumbersome. The purpose of the study is to determine if ZEGERID taken at bedtime offers an alternative option for the treatment of severe erosive esophagitis. The goal is to treat 100 subjects>
Poster P833: Retrospective Assessment of Immediate-Release Omeprazole/Sodium Bicarbonate in Improvement of GERD Symptoms in Patients Who Failed Delayed-Release Proton Pump Inhibitors
(J Jolley, MD) - Tuesday, October 27, 2009, 10:30 a.m. – 4:00 p.m. Pacific Time
This open-label retrospective review of medical records from 50 patients who failed one or more delayed-release proton pump inhibitors (PPIs) evaluated the effectiveness of ZEGERID 40 mg in controlling symptoms of gastroesophageal reflux disease (GERD).
Source: Santarus, Inc.
5d2b0a7c-f5c8-4287-8c7e-6b3c509a098b|0|.0
Posted in: Drug Trial News
Tags: Abdominal Pain, Diabetes, Diarrhea, Diet, Esophagitis, Exercise, Gastritis, Gastroenterology, Headache, Hypersensitivity, Metformin, Sodium Bicarbonate, Type 2 Diabetes, Ulcerative Colitis